Loading...
XSTO
CANTA
Market cap100mUSD
Dec 05, Last price  
3.80SEK
1D
-14.22%
1Q
49.02%
Jan 2017
-39.89%
IPO
-55.25%
Name

Cantargia AB

Chart & Performance

D1W1MN
XSTO:CANTA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.53%
Rev. gr., 5y
%
Revenues
0k
Net income
-162m
L-42.27%
-3,389,317-3,465,168-7,945,937-8,370,189-17,190,000-44,680,000-60,253,000-91,160,000-110,691,000-173,086,000-366,507,000-362,079,000-280,027,000-161,654,000
CFO
-163m
L-43.23%
-2,915,391-3,779,484-8,262,4866,897,877-30,277,000-39,528,000-41,103,000-104,686,000-111,254,000-156,387,000-346,445,000-358,915,000-286,664,000-162,752,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
URL
https://cantargia.com/
IPO date
Mar 17, 2015
Employees
24
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT